New Dissolution Apparatus for Pharmaceutical Quality Control

Agilent Technologies platform sets new global standard for dissolution

Published: Monday, November 15, 2010 - 14:00

(Agilent Technologies: Santa Clara, CA) -- Agilent Technologies Inc. has introduced the 708-DS Dissolution Apparatus, a quality control instrument that can be configured for manual and automated applications. The new device includes an improved design that minimizes variability and improves results. Dissolution is a technique used in the pharmaceutical industry to determine the rate at which pure active pharmaceutical ingredients dissolve.

“Agilent is committed to maintaining Varian’s tradition of excellence in dissolution and establishing a new standard for pharmaceutical companies and other firms operating in a global marketplace,” says Frank Riba, Agilent business manager of Dissolution Division. “The new 708-DS Dissolution Apparatus yields the sample-to-sample consistency that is critical for scientists assessing batch-to-batch performance, bioequivalency, and other characteristics of their compounds.”

The 708-DS Dissolution Apparatus is available as a basic manual model and in a variety of automated configurations for high-throughput online sampling and online ultra violet analysis. The apparatus allows for several advanced usage options, including temperature monitoring, automated dosage delivery and in-situ fiber optic analysis. Customized add-ons allow a variety of dosage types to be analyzed on the same apparatus.

The design of the 708-DS Dissolution Apparatus conforms to internationally harmonized pharmacopoeia specifications for basket, paddle, rotating cylinder, intrinsic, and paddle-over-disk configurations. The apparatus can test tablets, capsules, and a wide variety of other dosage forms.

In addition to the dissolution apparatus hardware and software, Agilent provides high-quality service for the DS-708 Dissolution Apparatus around the globe, including qualification documentation for the entire system; trained chemists to perform the installation and qualification; standard operating procedure templates; technical support for drug release methods, equipment, and regulatory questions; and sponsorship for the vendor-neutral online Dissolution Discussion Group forum.

For more information, visit www.chem.agilent.com.

Quality Digest does not charge readers for its content. We believe that industry news is important for you to do your job, and Quality Digest supports businesses of all types.

However, someone has to pay for this content. And that’s where advertising comes in. Most people consider ads a nuisance, but they do serve a useful function besides allowing media companies to stay afloat. They keep you aware of new products and services relevant to your industry. All ads in Quality Digest apply directly to products and services that most of our readers need. You won’t see automobile or health supplement ads.

Our PROMISE: Quality Digest only displays static ads that never overlay or cover up content. They never get in your way. They are there for you to read, or not.

So please consider turning off your ad blocker for our site.

Thanks,
Quality Digest

About The Author

Agilent Technologies

As the world’s premier measurement company, Agilent Technologies Inc. works in close collaboration with engineers, scientists, and researchers around the globe to meet the communications, electronics, life sciences, and chemical analysis challenges of today and tomorrow. The company operates two primary businesses—electronic and bio-analytical measurement—supported by Agilent Research Laboratories, its central research group. Agilent is committed to providing innovative measurement solutions that enable its customers and partners to deliver the products and services that make a measurable difference in the lives of people everywhere.